Volume : 10, Issue : 12, December – 2023

Title:

THE PATHOPHYSIOLOGY OF RHEUMATOID ARTHRITIS: ARTICLE REVIEW

Authors :

Abuobaida E.E. Abukhelaif, Ali Moteb S Alzahrani, Fahad Abdullah S Alghamdi, Ruba Saleh S Alghamdi, Ahmed Ali I Alghamdi, Khalid Ali S Alzahrani, Meshari Nasser A Allakhmi, Fadiyah Ahmed M Shabaan

Abstract :

Background: By delineating the interplay between genetic susceptibility, environmental triggers, and immune dysregulation, this theoretical framework provides a structured understanding of the pathophysiology of rheumatoid arthritis. It is a foundation for investigating potential therapeutic targets and developing interventions that address the intricate molecular and cellular processes involved in RA progression.
Objective: As we delve into the depths of RA’s pathophysiology, this review aims to synthesize recent findings and seminal contributions, providing a comprehensive overview of the current understanding of the molecular and cellular mechanisms driving this complex autoimmune disorder. By unraveling these intricacies, the contribution to this effort aimed at developing targeted therapeutic interventions and advancing the management of rheumatoid arthritis.
Methodology: Comprehensive research of the pathophysiology of rheumatoid arthritis. PUBMED and Google Scholar search engines were the main used databases for the search process, and articles were collected from 1990 to 2023. The terms used in the search were: Rheumatoid arthritis, Pathogenesis, Pathophysiology, Systemic Manifestations.
Conclusion: Unraveling the intricate pathophysiology of RA provides a foundation for advancing diagnostic and therapeutic strategies, ultimately improving the quality of life for individuals grappling with this challenging autoimmune disorder.
Keywords: Rheumatoid arthritis, Pathogenesis, Pathophysiology, Systemic Manifestations.

Cite This Article:

 

1. Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. The Lancet. 2016;388(10055):2023-38.
2. Gregersen PK, Silver J, Winchester RJ. The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum. 1987;30(11):1205-13.
3. McInnes IB, Schett G. The Pathogenesis of Rheumatoid Arthritis. New England Journal of Medicine. 2011;365(23):2205-19.
4. Schellekens GA, de Jong BA, van den Hoogen FH, van de Putte LB, van Venrooij WJ. Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. J Clin Invest. 1998;101(1):273-81.
5. Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J Clin Invest. 2003;111(12):1805-12.
6. Burrage PS, Mix KS, Brinckerhoff CE. Matrix metalloproteinases: role in arthritis. Front Biosci. 2006;11:529-43.
7. McInnes IB, Schett G. Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol. 2007;7(6):429-42.
8. McQueen F, Lassere M, Edmonds J, Conaghan P, Peterfy C, Bird P, et al. OMERACT Rheumatoid Arthritis Magnetic Resonance Imaging Studies. Summary of OMERACT 6 MR Imaging Module. J Rheumatol. 2003;30(6):1387-92.
9. Prevoo ML, van ‘t Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995;38(1):44-8.
10. Karlson EW, Lee IM, Cook NR, Manson JE, Buring JE, Hennekens CH. A retrospective cohort study of cigarette smoking and risk of rheumatoid arthritis in female health professionals. Arthritis Rheum. 1999;42(5):910-7.
11. Pedersen M, Jacobsen S, Klarlund M, Pedersen BV, Wiik A, Wohlfahrt J, et al. Environmental risk factors differ between rheumatoid arthritis with and without auto-antibodies against cyclic citrullinated peptides. Arthritis Res Ther. 2006;8(4):R133.
12. Tak PP, Kalden JR. Advances in rheumatology: new targeted therapeutics. Arthritis Res Ther. 2011;13 Suppl 1(Suppl 1):S5.
13. Ballara S, Taylor PC, Reusch P, Marmé D, Feldmann M, Maini RN, et al. Raised serum vascular endothelial growth factor levels are associated with destructive change in inflammatory arthritis. Arthritis Rheum. 2001;44(9):2055-64.
14. Bartok B, Firestein GS. Fibroblast-like synoviocytes: key effector cells in rheumatoid arthritis. Immunol Rev. 2010;233(1):233-55.
15. van Venrooij WJ, van Beers JJ, Pruijn GJ. Anti-CCP antibodies: the past, the present and the future. Nat Rev Rheumatol. 2011;7(7):391-8.
16. Nell VP, Machold KP, Stamm TA, Eberl G, Heinzl H, Uffmann M, et al. Autoantibody profiling as early diagnostic and prognostic tool for rheumatoid arthritis. Ann Rheum Dis. 2005;64(12):1731-6.
17. del Rincón ID, Williams K, Stern MP, Freeman GL, Escalante A. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum. 2001;44(12):2737-45.
18. Dimitroulas T, Sandoo A, Kitas GD. Asymmetric dimethylarginine as a surrogate marker of endothelial dysfunction and cardiovascular risk in patients with systemic rheumatic diseases. Int J Mol Sci. 2012;13(10):12315-35.
19. Aviña-Zubieta JA, Choi HK, Sadatsafavi M, Etminan M, Esdaile JM, Lacaille D. Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum. 2008;59(12):1690-7.
20. Turesson C, Jacobsson LT, Matteson EL. Cardiovascular co-morbidity in rheumatic diseases. Vasc Health Risk Manag. 2008;4(3):605-14.
21. Bongartz T, Nannini C, Medina-Velasquez YF, Achenbach SJ, Crowson CS, Ryu JH, et al. Incidence and mortality of interstitial lung disease in rheumatoid arthritis: a population-based study. Arthritis Rheum. 2010;62(6):1583-91.
22. Assayag D, Lee JS, King TE, Jr. Rheumatoid arthritis associated interstitial lung disease: a review. Medicina (B Aires). 2014;74(2):158-65.
23. Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med. 2005;352(10):1011-23.
24. Smith MA, Knight SM, Maddison PJ, Smith JG. Anaemia of chronic disease in rheumatoid arthritis: effect of the blunted response to erythropoietin and of interleukin 1 production by marrow macrophages. Ann Rheum Dis. 1992;51(6):753-7.
25. Zafirakis P, Foster C. Diagnosis and Treatment of Uveitis. Saunders, Philadelphia. 2002:632-52.
26. Dick AD, Tundia N, Sorg R, Zhao C, Chao J, Joshi A, et al. Risk of Ocular Complications in Patients with Noninfectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis. Ophthalmology. 2016;123(3):655-62.
27. Dammacco R, Guerriero S, Alessio G, Dammacco F. Natural and iatrogenic ocular manifestations of rheumatoid arthritis: a systematic review. Int Ophthalmol. 2022;42(2):689-711.
28. Matcham F, Rayner L, Steer S, Hotopf M. The prevalence of depression in rheumatoid arthritis: a systematic review and meta-analysis. Rheumatology (Oxford). 2013;52(12):2136-48.